Zepbound® vs Mounjaro®
Zepbound and Mounjaro are the same molecule (tirzepatide) from Eli Lilly — but differ in FDA indication, self-pay options, and cost. Here's the breakdown.
| Zepbound® | Mounjaro® | |
|---|---|---|
| Maker | Eli Lilly | Eli Lilly |
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA indication | Chronic weight management (+ OSA) | Type 2 diabetes |
| Mechanism | Dual GLP-1/GIP | Dual GLP-1/GIP |
| Self-pay / month | $299–$449 (LillyDirect) | ~$900–$1,080 (retail/GoodRx) |
| Retail list | ~$1,086 | ~$1,069–$1,080 |
| Weight-loss use | On-label | Off-label |
Pricing verified as of June 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
Clinical model
Both contain tirzepatide and act on the same dual GLP-1/GIP pathway. Zepbound is FDA-approved for chronic weight management (and obstructive sleep apnea); Mounjaro is FDA-approved for type 2 diabetes. Using Mounjaro for weight loss is off-label.
Pharmacy & fulfillment
Both are manufactured by Eli Lilly. Zepbound has a dedicated LillyDirect self-pay vial program ($299–$449/mo within the 45-day refill window); Mounjaro does not, so cash-pay relies on retail and GoodRx (~$900–$1,080). For compounded tirzepatide cost context, see compounded tirzepatide cost (not FDA-approved).
Strengths and trade-offs
Zepbound®
- FDA-approved for weight management
- Lower self-pay via LillyDirect ($299–$449)
- Also approved for sleep apnea
- Self-pay requires 45-day refill window for best price
- Still costlier than compounded cash-pay
Mounjaro®
- FDA-approved for type 2 diabetes
- May be covered when prescribed for diabetes
- No dedicated self-pay program
- Off-label for weight loss
- Higher cash cost than Zepbound self-pay
Who each may be best for
Zepbound is the on-label brand choice for weight management with the cheaper self-pay route. Mounjaro is the on-label choice for type 2 diabetes. Same molecule either way; a licensed clinician decides what is appropriate.
Questions
Are Zepbound and Mounjaro the same drug?
Both contain tirzepatide and work identically. The difference is FDA indication (Zepbound for weight, Mounjaro for type 2 diabetes) and the resulting pricing/coverage. See NexLife pricing
Which is cheaper for weight loss?
For weight management, Zepbound's LillyDirect self-pay ($299–$449/mo) is usually cheaper than cash-pay Mounjaro (~$900–$1,080/mo).
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.